Nutrition ingredients supplier Balchem's Q1 sales rise 8%, beat estimates

Balchem

30/04/2026 12:25

Overview

US nutrition ingredients supplier's fiscal Q1 sales rose 8%, beating analyst expectations

Adjusted EPS for fiscal Q1 rose to $1.33 from $1.22 yr/yr

Company saw growth in all three business segments, with record Q1 sales and earnings

Outlook

Company did not provide specific financial guidance for the current quarter or full year

Result Drivers

SEGMENT SALES GROWTH - Higher sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments drove overall revenue growth

MANUFACTURING EFFICIENCIES - Gross margin improvement was primarily due to sales growth and manufacturing efficiencies, partially offset by raw material inflation

HIGHER OPERATING EXPENSES - Operating expenses rose mainly due to higher compensation-related costs and increased professional services

Company press release: ID:nGNX6VgTXq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$270.70 mln
$266.50 mln (3 Analysts)
Q1 EPS
$1.25
Q1 Net Income
$40.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy"

Wall Street's median 12-month price target for Balchem Corp is $202.50, about 16.8% above its April 29 closing price of $173.33

The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 28 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)